PROTOCOL TO EVALUATE TOXICITY, BIOLOGIC EFFECT AND EFFICACY OF ANTI-CD6-BR

这是一项使用抗CD 6阻断剂的I期开放标签剂量递增试验， 蓖麻毒素（抗CD 6-bR）治疗皮肤T细胞 淋巴瘤（CTCL）抗-CD-bR是一种IgG 2a鼠单克隆抗体， 具有与封闭的蓖麻毒素共价连接的Veeb。和静脉给以 抗CD 6-bR将通过中心静脉连续给药5天 导尿管将获得血清药代动力学数据，用于分析 首次给药。将随访血清Hm和HARA水平 在整个治疗过程中。

This is a Phase I open-label dose-escalation trial using Anti-CD6-blocked Ricin (Anti-CD6-bR) in the treatment of patients with cutaneous T-cell lymphoma(CTCL) Anti-CD-bR is an IgG2a murine monoclonal antibody which has veeb covalently linked to blocked ricin. Intravenous doses of Anti-CD6-bR will be given continuously for 5 days via central venous catheter. Serum pharmacokinetics will be obtained for analysis with the 1st dose administered. Serum Hm and HARA levels will be followed throughout treatment.